The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse ...
A new bipartisan bill could end the import of primates for U.S. research, targeting the roughly 20,000 monkeys brought into the country each year for laboratories or their suppliers. | A new ...
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides. The British drugmaker is paying $55 million upfront to China’s ...
In the last three years, CellCentric CEO Will West has been on a journey that has transformed how he thinks about the future ...
A phase 2 trial of Avalo Therapeutics’ hidradenitis suppurativa (HS) candidate hit its primary endpoint, emboldening the ...
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...
The winding road of BioCryst Pharmaceuticals’ avoralstat has come to an end. | The company announced it has concluded ...
Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the ...
Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of ...
Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...
Gilead will lay off 108 workers from Arcellx’s site at 800 Bridge Parkway in Redwood City, CA, according to a Worker ...
Johnson & Johnson MedTech is touting positive results from the first clinical study of its Ottava soft-tissue surgical robot, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results